Light-chain cardiac amyloidosis: a case report of extraordinary sustained pathological response to cyclophosphamide, bortezomib, and dexamethasone combined therapy

BACKGROUND: Heart involvement represents the most ominous prognostic factor in light-chain amyloidosis (AL), often foreclosing curative therapies such as high-dose chemotherapy followed by autologous stem cell transplantation (ASCT). Heart transplantation (HTx) may be considered before ASCT in rigor...

Descripción completa

Detalles Bibliográficos
Autores principales: Porcari, Aldostefano, Pagura, Linda, Rossi, Maddalena, Porrazzo, Marika, Dore, Franca, Bussani, Rossana, Merlo, Marco, Sinagra, Gianfranco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Grand Round
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149786/
https://www.ncbi.nlm.nih.gov/pubmed/35652085
http://dx.doi.org/10.1093/ehjcr/ytac130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149786/
https://www.ncbi.nlm.nih.gov/pubmed/35652085
http://dx.doi.org/10.1093/ehjcr/ytac130

Ejemplares similares